Advertisement
Fewer American families are struggling to pay medical bills

CDC: Fewer Americans Struggling With Medical Bills

0
U.S. report shows 12 million are no longer in families having trouble paying for health care
Kanuma (sebelipase alfa) has been approved by the U.S. Food and Drug Administration as the first treatment for LAL deficiency (Wolman disease or cholesteryl ester storage disease).

FDA Approves Kanuma for Lysosomal Acid Lipase Deficiency

0
For treatment of LAL deficiency, also known as Wolman disease or cholesteryl ester storage disease
Statin treatment is associated with reduced risk of incident cataract development

Statin Treatment Linked to Reduced Risk of Cataracts

0
Simvastatin plus ezetimibe linked to lower risk of cataract development versus placebo
All children should be screened for high cholesterol

AAP: Screen All Children for Cholesterol, Depression, HIV

0
American Academy of Pediatrics guidelines reflect concerns about obesity, suicide
Participation in the endurance competition known as the Ultraman is associated with dramatic alterations in body composition

Endurance Athletes May Suffer Dangerous Metabolic Effects

0
'Ultraman' competitors experience muscle damage and insulin resistance, researchers find
Very old patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) have increased rates of PCI failure

Poor PCI Outcomes Up for Very Old With STEMI

0
However, successful percutaneous coronary intervention benefits all age groups
Nearly half of American adults who should be taking cholesterol-lowering drugs don't

CDC: Too Few Taking Needed Cholesterol-Lowering Drugs

0
Only half who should are using medications to help prevent cardiovascular disease
Large clinical studies that are sponsored by industry are more likely to report favorable outcomes and less likely to report unfavorable outcomes than those sponsored by the National Institutes of Health

Cardiovascular Trial Sponsorship Significantly Impacts Findings

0
Favorable outcomes seven times more likely in industry- versus NIH-sponsored trials
The addition of lixisenatide to usual care does not impact the rate of major cardiovascular events or other serious adverse events among patients with type 2 diabetes and a recent acute coronary syndrome

Lixisenatide Doesn’t Affect Cardiovascular Risk in T2DM

0
Findings among patients with type 2 diabetes and recent acute coronary syndrome
A case before the Supreme Court is potentially threatening patient confidentiality

AMA: Case Before Supreme Court Threatens Patient Privacy

0
Case involves Medical Board obtaining three years of prescribing history for doctor, after single complaint